

has it all...

# LANZO<sup>®</sup>

Lansoprazole

## Abidi



- ✓ Highest number of FDA approved indications <sup>1</sup>
- ✓ High efficacy and rapid acid-related symptoms relief <sup>2</sup>
- ✓ Rapid onset of action <sup>2</sup>
- ✓ As safe as placebo <sup>3</sup>
- ✓ Very low drug interactions <sup>3</sup>
- ✓ No interaction with Clopidogrel based on FDA label 2012 <sup>4</sup>
- ✓ Class B in pregnancy <sup>1</sup>



**abidi** | Leading Innovation  
SINCE 1946 | Leading Quality

1. Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer Health, Inc; 2011. p 1975.  
2. Richter Joel E, Kahrlas Peter J, Sontag Stephen J, et al. Comparing Lansoprazole and Omeprazole in Onset of Heartburn Relief. Am J Gastroenterol 2001; 96: 3089-3098.  
3. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 2006; 29: 769-784.  
4. Lansoprazole: highlight of prescribing information. FDA label 2012; Reference ID: 3193013.

# Pegaferon<sup>®</sup> 180mcg

Cornerstone of Chronic Hepatitis C Therapy



Now  
available in  
Prefilled syringe



تحت پوشش ۹۰ درصدی بیمه‌های تامین اجتماعی، خدمات درمانی و نیروهای مسلح  
دارای گواهی تایید کیفیت از مراکز معتبر بین المللی نظارت بر ساخت داروهای بیوتکنولوژی از اروپا

شرکت فرآورده های پویش دارو • تهران-ایران  
Pooyesh Darou Biopharmaceutical Co. • Tehran-Iran  
021-88 970 980 • [www.pooyeshdarou.com](http://www.pooyeshdarou.com)





محصول  
دانمارک

CHR HANSEN  
Denmark



فور بیوکپ®

از امروز

در داروخانه های سراسر کشور

امور مشتریان و هماهنگی جهت سفارش:

۲۲۲۲۰۳۱۸ - ۲۲۲۷۸۸۰۳

کامل ترین  
سوش های  
پروبايوتیک

4 biocap®  
Probiotic

تأثیر فوق العاده بر :

● سندرم روده تحریک پذیر (IBS)

● عوارض مصرف آنتی بیوتیک

● رفع یبوست

● نفخ شکم

● اسهال مسافرتی

● تقویت سیستم ایمنی بدن

● بهبود علایم گوارشی بعد از جراحی

● بهبود علایم گوارشی در افراد کم تحرک

● بدون نیاز به نگهداری در یخچال



بسته بندی در :  
Tehran Darou  
Pharmaceutical Co.  
شرکت داروسازی تهران دارو



www.4biocap.com




# ELECTROSUGERY/WATERJET SURGERY

## ESD WORKSTATION WITH HYBRID KNIFE

Endoscopic Submucosal Dissection

4 WORKING STEPS - 1 INSTRUMENT



THE COMPLETE PACKAGE FOR ALL GIT INTERVENTIONS



GI Workstation - fully equipped

VIO 200 D

APC 2

ERBEJET 2

EIP 2

# ERBE



شرکت پیشرفت درمان  
Pishraff Darman Co.

تهران: خیابان دکتر بهشتی، خیابان قنبرزاده،  
کوچه دوازدهم، پلاک ۲۵

تلفن: ۰۴-۸۸۷۵۸۰۷۰ نامبر: ۸۸۷۶۰۳۸۴



Mild-moderate ulcerative colitis

**ASACOL**<sup>TM</sup>

mesalazine

On Target for Remission



**9** OUT OF **10 ASACOL**<sup>TM</sup> patients maintain  
clinical remission at 6 months<sup>(1)</sup>





For IBD patients

*Get the good life back*



**Pentasa**<sup>®</sup>  
mesalazine

**FERRING**  
PHARMACEUTICALS

Further information is available at:

Ferring Middle East  
P.O.Box 850845, Amman 11185 - Jordan  
Tel: +962 6 5501000, Fax: +962 6 5501015  
E-mail: [marketingme@ferring.com](mailto:marketingme@ferring.com)  
Website: [www.ferringme.com](http://www.ferringme.com)

CPH-165-349-12/09

**Abbreviated Prescribing Information**

**Presentations:** Prolonged release 500 mg Tablets, prolonged release 1g Sachets, prolonged release 2g Sachets, 1g Suppositories, and 1g/100 ml Enema. **Uses:** **Tablets & Sachets:** Chronic Inflammatory Bowel Disease (Ulcerative Colitis & Crohn's Disease). **Suppositories:** Chronic Inflammatory Bowel Disease located to the Rectum (Ulcerative Proctitis). **Enema:** Ulcerative Proctosigmoiditis. **Contraindications:** Hypersensitivity to mesalazine, any of the excipients, or salicylates. Severe liver or renal impairment. **Dosage:** **Tablets: Ulcerative Colitis: Treatment of Active Disease: Adults:** 2g mesalazine per day, divided into two single doses. In case of insufficient response, the dose can be increased to 4g daily. **Relapse Prophylaxis:** In general, 1.5g mesalazine, divided into 2-3 single doses. **Crohn's Disease: Treatment of Active Disease: Adults:** Up to 4g mesalazine per day, divided into 2-3 single doses. **Sachets 1g & 2g: Ulcerative Colitis: Treatment of Active Disease: Adults:** Individual Dosage, up to 4g mesalazine daily divided into 2-4 doses. **Maintenance Treatment: Adults:** Individual Dosage. Recommended dosage, 2 g mesalazine once daily. **Crohn's Disease: Treatment of Active Disease: Adults:** Individual dosage, up to 4g mesalazine daily in divided dose. **Maintenance Treatment: Adults:** Individual dosage, up to 4g mesalazine daily in divided dose. **Tablets & Sachets: Ulcerative Colitis & Crohn's Disease: Treatment of Active Disease: Children:** Children 6 years of age and older: To be determined individually, starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. The total dose should not exceed 4 g/day (maximum adult dose). **Maintenance Treatment: Children:** Children 6 years of age and older: To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed 2 g/day (recommended adult dose). **Enema:** 1 enema at bed time. **Suppositories:** One suppository 1-2 times/day. **Special Warnings and Precautions:** Caution is recommended when treating patients allergic to sulphasalazine (risk of allergy to salicylates). Caution is recommended in patients with impaired liver function. The drug is not recommended for use in patients with renal impairment. Mesalazine-induced cardiac hypersensitivity reactions (myo- and pericarditis) have been reported rarely. Serious blood dyscrasias have been reported very rarely with mesalazine. **Adverse Reactions: Tablets:** Occasional adverse reactions seen in clinical trials are diarrhea, nausea, abdominal pain, headache, vomiting, and rash. **Hypersensitivity reactions and drug fever may occasionally occur. Sachets 1g:** The most frequent adverse reactions seen in clinical trials are diarrhea, nausea, abdominal pain, headache, vomiting, and rash. **Sachets 2g:** Nervous System: Occasional: headache, nausea, dizziness. **Enema:** Occasionally, reactions of the central nervous system such as headache and vertigo as well as gastro-intestinal impairments (diarrhea, abdominal pain, nausea, vomiting) and rash (allergic exanthema, urticaria) have been observed. **Suppositories:** Pentasa suppositories are generally well tolerated, in 1-3% of patients diarrhea, nausea abdominal pain, headache, vomiting and rash, e.g. urticaria and eczema have been observed.